Skip to main content
SpringerLink
Log in

Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

To study the role of SHP-1 methylation in the pathogenesis of myelodysplastic syndromes (MDS), we detect the methylation status of SHP-1 promoter and STAT3 phosphorylation of MDS patients by the methylation-specific PCR and Western blotting, respectively. It is found that the methylation rate of SHP-1 promoter of high-risk MDS patients (69.2%) was higher than that of the low-risk MDS patients (21.4%) (P = 0.001). The expression rate of STAT3 phosphorylated protein of high-risk group was higher (66.7%), when compared with that of the low-risk group (18.2%) (P = 0.0001). Correlation analysis showed that the methylation status of SHP-1 promoter is positive correlated with the expression of phosphorylated STAT3 in MDS patient (P < 0.001, r = 0.55). Interestingly, in high-risk group, the Kaplan–Meier analysis showed that the 3-year overall survival rate of high-risk MDS patients with SHP-1 methylation was lower than that of patient without SHP-1 methylation (25% vs. 61%) (P = 0.033). In summary, it is indicated that the SHP-1 methylation plays important role in the pathogenesis of MDS via activating the JAK/STAT pathway probably and the methylation of SHP-1 promoter is a useful prognostic factor for high-risk MDS patient, with the characteristic of higher methylation lower survival rate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    Article  PubMed  CAS  Google Scholar 

  2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28.

    Article  PubMed  CAS  Google Scholar 

  3. Lin J, Yao DM, Qian J, Wang YL, Han LX, Jiang YW, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res. 2008;32:1541–5.

    Article  PubMed  CAS  Google Scholar 

  4. Wu SJ, Yao M, Chou WC, Tang JL, Chen CY, Ko BS, et al. Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol. 2006;135:317–23.

    Article  PubMed  CAS  Google Scholar 

  5. Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol. 2006;76:23–32.

    Article  PubMed  CAS  Google Scholar 

  6. Grovdal M, Khan R, Aggerholm A, et al. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res. 2007;13:7107–12.

    Article  PubMed  Google Scholar 

  7. Wu C, Sun M, Liu L, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 2003;306:1–12.

    Article  PubMed  CAS  Google Scholar 

  8. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474–88.

    Article  PubMed  CAS  Google Scholar 

  9. Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002;109:1139–42.

    PubMed  CAS  Google Scholar 

  10. Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, et al. Gene silencing of the tyrosine phosphastase SHP1 by aberrant methylation in leukemias/lymphomas. Cancer Res. 2002;62:6390–4.

    PubMed  CAS  Google Scholar 

  11. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 2004;103:4630–5.

    Article  PubMed  CAS  Google Scholar 

  12. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002;168:466–74.

    PubMed  CAS  Google Scholar 

  13. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143–64.

    Article  PubMed  CAS  Google Scholar 

  14. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Natl Rev Mol Cell Biol. 2002;3:651–62.

    Article  CAS  Google Scholar 

  15. Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, Su WC. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer. 2003;89:344–9.

    Article  PubMed  CAS  Google Scholar 

  16. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 2000;95:3765–70.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (30672208 and 81100337).

Conflict of interest

All authors have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology, Tianjin Cancer Hospital and Institute, Tianjin Medical University, Tianjin, 300060, People’s Republic of China

    Yizhuo Zhang, Haifeng Zhao, Weipeng Zhao, Yafei Wang & Bing Xia

  2. Department of Hematology, First Affiliated Hospital of Chinese Peoples Liberation Army General Hospital, Beijing, People’s Republic of China

    Dandan Zhao & Xiaoxiong Wu

  3. Department of Hematology, General Hospital of the People’s Liberation Army, Beijing, People’s Republic of China

    Wanming Da

Authors
  1. Yizhuo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dandan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haifeng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoxiong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weipeng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yafei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bing Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wanming Da
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yizhuo Zhang.

Additional information

Yizhuo Zhang, Dandan Zhao and Haifeng Zhao are contributed equally to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, Y., Zhao, D., Zhao, H. et al. Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis. Med Oncol 29, 2359–2363 (2012). https://doi.org/10.1007/s12032-012-0163-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0163-6

Keywords

Search

Navigation